Quick answer · /answers/ cluster · Regulatory status
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not an FDA-approved product — approval and the STEP-trial evidence (the ~15%-class averages) belong to Wegovy and Ozempic. With the semaglutide shortage declared resolved in early 2025, compounded versions generally proceed under 503A patient-specific prescriptions; the April 2026 FDA compounding proposal (comments closed July 30, 2026) has produced no final rule as of this writing. The honest formulation this site uses everywhere: same intended active ingredient, not the same medication — and every price we publish travels with that line attached.
The practical checklist that follows from “not approved”: verify the pharmacy (the guide), confirm the prescription is patient-specific, and weigh the brand lane honestly — Wegovy’s $499 cash lane versus the $119 audited compounded floor is a $380/month decision with real goods on both sides. Coverage first, always: commercial savings cards reach ~$25-class for covered patients, which beats every cash number.